Relevant bibliographies by topics / Hepatitis C – Patients

Academic literature on the topic 'Hepatitis C – Patients'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatitis C – Patients.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hepatitis C – Patients"

1

Nouman, Muhammad Khuram, Bushra Zaidi, Ghulam Mohiuddin, Faryal Asif, and Muhammad Khan Malik. "HEPATITIS C." Professional Medical Journal 25, no. 03 (March 10, 2018): 387–91. http://dx.doi.org/10.29309/tpmj/2018.25.03.381.

Full text
Abstract:
Background: Hepatitis C virus (HCV) is the most communal source of non-A,non-B viral hepatitis in the world. The disease is illusory, and the majority of patients do notacquire jaundice at its onset. Treatment of hepatitis C with interferon attained a sustainedvirological response (SVR) in almost 50% of the patients with HCV infection. Viral genotype isimportant to determine the response. The present study aims to provide the incidence of relapseof HCV in patients taking interferon therapy and to identify the predictors for relapse. StudyDesign: Retrospective observational study. Setting: Department of Medicine, DHQ TeachingHospital, Sargodha. Period: Two years. Methods: A total of 60 patients were retrospectivelyevaluated for this study. The exclusion criteria include the patients co- infected with hepatitisB virus or HIV. All the patients were monitored 2, 4, 8, 12, 16, and 24 weeks after the endof treatment with interferon alpha. Results: We observed that the patients with relapse weresignificantly older and heavier (P value < 0.05). At the start of treatment, viral load was higherin relapsed patients (P value < 0.04). Conclusion: On the bases of our study findings, we canconclude that low incidence of relapse occurred with interferon therapy. High ALT level, viralloads, older age and obesity were some of strong predictors of relapse among HCV patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Dudanova, Olga Petrovna, Marina E. Marina, Maria M. Pisareva, and Mikhail P. Grudinin. "Extrahepatic manifestations in patients with chronic hepatitis C." Journal of Biomedical Technologies, no. 1 (June 2014): 18–24. http://dx.doi.org/10.15393/j6.art.2014.3001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

MEHBOOB, FATIMA, and ZAFAR MAJEED BABA BABAR. "HEPATITIS C PATIENTS;." Professional Medical Journal 15, no. 01 (March 10, 2008): 61–66. http://dx.doi.org/10.29309/tpmj/2008.15.01.2698.

Full text
Abstract:
Objectives: To determine the impact of antiviral treatment of Hepatitis C patients with poor socioeconomic resources. Design: Prospective cohort study. Place and Duration: Department of Medicine, Sheikh ZayedMedical College / Hospital, Rahim Yar Khan, from August 2006 to February 2007. Subjects and Method:One hundredknown cases of hepatitis C were selected. PCR and biochemical tests were performed before the start of therapy.Interferon and Ribavirin therapy was given according to standard therapeutic protocol. Patients were continuouslymotivated and educated for regular treatment. The observations were collected regularly. Results: Out of hundredcases 95 improved symptomatically. One got worse while 4 remained symptomatic. At the end of therapy PCR wasperformed only in 4 cases. Conclusion: In non affording patients although exact status of viral clearance is not knownbut some thing is better than nothing rule was applied for treatment of patients
APA, Harvard, Vancouver, ISO, and other styles
4

Nouman, Muhammad Khuram, Bushra Zaidi, Ghulam Mohiuddin, Faryal Asif, and Muhammad Khan Malik. "HEPATITIS C;." Professional Medical Journal 25, no. 03 (March 6, 2018): 387–91. http://dx.doi.org/10.29309/tpmj/18.4065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Khan, Momin, Abdul Jabbar, Bacha Amin Khan, Abdul Ahad, and Fazal Akbar. "HEPATITIS C;." Professional Medical Journal 25, no. 04 (April 8, 2018): 484–88. http://dx.doi.org/10.29309/tpmj/18.4293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Leite, Juliana Mayara da Silva, Jéssica de Oliveira Inácio, Raissa Silva De Melo Monteiro, Cristiane da Câmara Marques, Vanessa Pinheiro Barreto, and Alexsandra Rodrigues Feijão. "Sociodemographic and clinical characterization of patients with chronic hepatitis C." Enfermería Global 18, no. 3 (June 6, 2019): 157–94. http://dx.doi.org/10.6018/eglobal.18.3.316971.

Full text
Abstract:
Objetivo: Describir la caracterización sociodemográfica y clínica de los pacientes portadores de hepatitis C crónica acompañados en el ambulatorio de un hospital de referencia en infectología. Método: Estudio transversal, descriptivo, cuantitativo, con usuarios portadores de hepatitis C crónica asistidos en el ambulatorio de un hospital de referencia durante noviembre de 2015 a abril de 2016 con una muestra de 47 usuarios. Resultados: Los participantes son de sexo masculino (76,6%) con rango de edad superior a 57 años (57,5%), pardo (38,3%), casado (55,3%), con grado de escolaridad (31,9%), y residente en la capital (61,7%), con tiempo de descubrimiento de hasta 6 años (68,1%), desconociendo la forma de contaminación (57,5%), inmunizado contra la hepatitis B (65,9%), realizando tratamiento medicamentoso (85,1%) con Ribavirina (55,6%); Y el 70,2% presentó efectos adversos. Conclusión: La caracterización sociodemográfica y clínica auxilian en la práctica clínica del equipo multiprofesional con los portadores de hepatitis C crónica. Objective: To describe the sociodemographic and clinical characterization of patients with chronic hepatitis C followed at the outpatient clinic of a reference hospital in infectology.Method: A cross-sectional, descriptive, quantitative study with chronic hepatitis C patients attended at a referral hospital during November 2015 to April 2016 with a sample of 47 users. Results: The participants were male (76.6%), 57 years old (57.5%), brown (38.3%), married (55.3%), (61.7%), with a discovery time of up to 6 years (68.1%), not knowing the form of contamination (57.5%), immunized against hepatitis B (65.9%), undergoing drug therapy (85.1%) with Ribavirin (55.6%); And 70.2% had adverse effects. Conclusion: Sociodemographic and clinical characterization assist the clinical practice of the multiprofessional team with patients with chronic hepatitis C Objetivo: Descrever a caracterização sociodemográfica e clínica dos pacientes portadores de hepatite C crônica acompanhados no ambulatório de um hospital referência em infectologia. Método: Estudo transversal, descritivo, quantitativo, com usuários portadores de hepatite C crônica assistidos no ambulatório de um hospital referência durante Novembro 2015 a Abril de 2016 com uma amostra de 47 usuários. Resultados: Os participantes encontram-se no sexo masculino (76,6%) com faixa etária acima de 57 anos (57,5%), pardo (38,3%), casado (55,3%), com grau de escolaridade fundamental incompleto (31,9%), e residente na capital (61,7%), com tempo de descoberta de até 6 anos (68,1%), desconhecendo a forma de contaminação (57,5%), realizando tratamento medicamentoso (85,1%) com Ribavirina (55,6%); e 70,2% apresentaram efeitos adversos. Conclusões: A caracterização sociodemográfica e clínica auxiliam na prática clínica da equipe multiprofissional com os portadores de hepatite C crônica.
APA, Harvard, Vancouver, ISO, and other styles
7

Jamali, Ghulam Mustafa, Anwar Ali Jamali, and Habibullah Shaikh. "HEPATITIS C VIRUS;." Professional Medical Journal 24, no. 11 (November 3, 2017): 1621–29. http://dx.doi.org/10.29309/tpmj/2017.24.11.646.

Full text
Abstract:
Objectives: The plan of this current research was in the direction for towards theassessment of the existing ELISA (Enzyme Linked Immunosorbant Assay) method throughantibodies testing for identification of hepatitis C virus disease by comparing their outcome withthe Real Time polymerase chain reaction analysis. Setting: Peoples Medical College HospitalNawabshah. Period: December 2015 to December 2016. Methods: In this current research 100blood samples were analyzed due to the presence of anti-HCV antibodies by 3rd-generationenzyme-linked immunosorbent assay testing. All the specimens were 100% positive. Polymerasechain reaction test was performed according to the laboratory directions in anti- hepatitis C virusantibodies positive patients to validate the diagnosis of hepatitis C virus infectivity. Results: Thisresearch shows that, the entire results were positive by Enzyme Linked Immunosorbant Assaytesting. As compared with polymerase chain reaction the of Enzyme Linked ImmunosorbantAssay in this research the screening test for anti hepatitis C virus - antibodies is about 2%false positive. Out of the 100 samples 98 cases are positive by Real Time polymerase chainreaction analysis while only 02 cases report are negative (2%). Conclusion: The proportion ofhepatitis C virus infectivity was 100% by 3rd-generation enzyme-linked immunosorbent assaytesting, 98% by Real Time polymerase chain reaction analysis. As in our research the hepatitisC virus –Ribonucleic acid is present in 98% cases who are the Anti- hepatitis C virus antibodiespositive patients, it can be suggested that Anti-HCV antibodies detection by third generationELISA technique in routine procedure is sufficient to determine HCV infection.
APA, Harvard, Vancouver, ISO, and other styles
8

Rajput, Aisha, Bagwan Das, Santosh Kumar, Rafique Ansari, Beshan Kumar, and Abdul Qadeer. "VIRAL HEPATITIS C PATIENTS." Professional Medical Journal 23, no. 10 (October 10, 2016): 1263–68. http://dx.doi.org/10.29309/tpmj/2016.23.10.1739.

Full text
Abstract:
Objectives: To determine the frequency of hypothyroidism in patients with viralhepatitis receiving interferon treatment. Study Design: Descriptive cross sectional. Setting:Department of Medicine, Jinnah Postgraduate Medical Centre, Karachi. Duration of Study: Sixmonths. Subjects and Methods: All patients with age 30 to 60 years of either gender havingpersistent or intermittent elevation of alanine arninotransferase (ALT, the upper limit of normalALT is 40 IU/L) over a six-month period and Anti-HCV positivity and detection of HCV-RNA inthe sera On IFN-α mono therapy for more than 3 months were enrolled. History of duration ofdisease and treatment was obtained from patients. A 3 cc blood sample of Patients were drawnand send for TSH level. Presence of TSH level >4.0 miU/L was labelled as Hypothyroidism.Results: Mean age of the patients was 51.79±7.96 years. There were 51 (43.60%) males and 66(56.40%) females. Mean TSH level was 3.98±0.23 mIU/L. Mean duration of HCV was 6.42±1.67months. Mean duration of treatment was 5.42±1.67 months. Frequency of hypothyroidism wasfound in 62 (53%) patients. Conclusion: The frequency of hypothyroidism in patients with viralhepatitis receiving interferon treatment was found to be 62 (53%).
APA, Harvard, Vancouver, ISO, and other styles
9

Al-Kenani, Heyam Qaid Mohammed. "Diagnosis of Candidiasis and Hepatitis C virus in Thalasemia Patients." International Journal of Psychosocial Rehabilitation 24, no. 5 (April 20, 2020): 3954–61. http://dx.doi.org/10.37200/ijpr/v24i5/pr2020105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Boshnak, Noha H. "Reticulated Platelets in Egyptian Patients with Chronic Hepatitis C Infection." Journal of Medical Science And clinical Research 05, no. 02 (February 15, 2017): 17664–71. http://dx.doi.org/10.18535/jmscr/v5i2.75.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hepatitis C – Patients"

1

Nilsson, Sara, and Johanna Persson. "Vilka erfarenheter patienter med hepatit C har av bemötandet i vården." Thesis, Högskolan Kristianstad, Sektionen för hälsa och samhälle, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-13537.

Full text
Abstract:
Bakgrund: Den vanligaste smittvägen för hepatit C är genom intravenöst drogmissbruk. Smittöverföring kan även ske via blodtransfusioner eller stickskador i vården. Det finns många fördomar förknippade med sjukdomen och risken är stor att dessa färgar mötet med patienter. Det är viktigt att som vårdpersonal vara medveten om hur den egna synen på sjukdomen kan påverka bemötandet. Syfte: Syftet var att belysa vilka erfarenheter patienter med hepatit C har av bemötandet i vården. Metod: Studien utformades som en allmän litteraturöversikt av tolv kvalitativa artiklar. Manifest innehållsanalys användes. Resultat: Patienter med HCV hade blandade erfarenheter av mottagandet: välkomnande, avvisande eller otryggt. Vidare ledde detta till erfarenheter av stöd eller diskriminering. Patienter kunde ha erfarenheter av professionellt stöd eller brist på professionellt stöd. Diskriminering kunde orsakas av antingen vårdpersonal eller organisation. Slutsats: På grund av stigmatisering kring sjukdomen är patienter med hepatit C en utsatt grupp i samhället. Vårdpersonalens kunskap är en viktig del i bemötandet. Det krävs utbildning för att kunna erbjuda en mer holistisk vård vid hepatit C än i dagsläget. Genom ökad kunskap kring både sjukdom och bemötande kan bemötandet påverkas positivt, det vill säga: mottagandet blir bättre, stödet ökar och diskrimineringen minskar.
Background: The most common route of transmission of hepatitis C is through intravenous drug abuse. Transmission can also occur through blood transfusion. There are many prejudices associated with hepatitis C. Chances are that this colors interactions with patients. It is important that healthcare professionals are aware of how their own perception of the disease may affect the encounter.  The Objective was to highlight the experiences patients with hepatitis C have of the encounter in the healthcare. Method: The study was designed as a general literature review of twelve qualitative articles. Manifest content analysis was used. Results: Patients with hepatitis C had mixed experiences of receipt: welcoming, rejecting or unsafe. This led to experiences of support or discrimination. Patients experienced professional support or lack of professional support. Discrimination could be caused either by healthcare professionals or the organization. Conclusion: Because of stigma surrounding the disease patients with hepatitis C are a vulnerable group in society. The knowledge of healthcare professionals is an important part of the encounter. It requires training to provide holistic care for hepatitis C. Increased knowledge about both the disease and patient-professional relation can positively affect the encounter: the reception gets better, support increases and discrimination is reduced.
APA, Harvard, Vancouver, ISO, and other styles
2

Yuen, King-tai, and 袁敬弟. "A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193555.

Full text
Abstract:
The cost effectiveness of using novel HCV treatment option, telaprevir and boceprevir, should depend on patients’ respond to conventional PEG-INFα and ribavirin therapy. The study of pharmacogenomics, interleukin-28B (IL-28B) polymorphisms, accompanied with the information of HCV genotypes are suggested to have the strongest predictive value of treatment outcomes and prognosis of disease in individuals infected with HCV who are undergoing conventional PEG-INFα and ribavirin therapy. It is extremely valuable in HCV/HIV co-infected patients as these groups of patients require a complex treatment regimen and demonstrate poor sustained viral response (SVR) rate. The development of a fast and promising IL-28B genotyping assay is urgently needed. A total of 47 blood samples randomly selected from HCV and HIV co-infected patients were used in this investigation. The aims of this study are to evaluate and compare the performance of newly developed IL-28B HybProbe real-time PCR assay using LightCycler® system against Sanger Sequencing method in determining IL-28B polymorphisms on rs12979860 and rs8099917 and to estimate the prevalence of IL-28B polymorphisms among HCV/HIV co-infected patients in Hong Kong. In addition, the genotypic distribution of HCV among the same patient group is identified by using in-house Sanger Sequencing method. It was found that the newly developed IL-28B real-time HybProbe assay resulted in 100% concordance with the traditionally used Sanger Sequencing method. The allele frequencies of C and T were 96% and 4% in rs12979860 and T and G were 97% and 3% in rs8099917 respectively. The CC and TT wild type are predominating in rs12979860 and rs8099917 with frequencies of 93.62% and 95.74% respectively. The most favorable compound genotype CC/TT with both homozygous wild types on both SNPs was the most predominant type with a high prevalence of 93.61%. Among all the samples, 50% samples were found to be HCV genotype 1, 41.18% were genotype 6 and 8.82% were genotype 3. A simple and efficient IL-28B real-time HybProbe assay was developed in this study and proved to show excellent performance on IL-28B genotyping although further optimization is suggested before it can be applied in the clinical setting. The favourable wild type genotypes of rs12979860 and rs8099917 accounted for the most predominant genotypes which is similar to other findings obtained from an Asian population. A comparatively high prevalence of HCV genotype 6 was found in the HCV/HIV co-infected group. Future study with the information of treatment outcomes (HCV viral load) can further evaluate the predictive value of IL-28B polymorphisms on SVR in different HCV genotypes.
published_or_final_version
Medical Sciences
Master
Master of Medical Sciences
APA, Harvard, Vancouver, ISO, and other styles
3

Telfer, Paul. "Clinical studies of hepatitis C virus infection in haemophilic patients." Thesis, University of Oxford, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388895.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Herreru-Martínez, Esteban. "Hepatitis C and HIV co-infection in patients with haemophilia." Thesis, University College London (University of London), 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.404936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sgorbini, Myra. "Living with Hepatitis C and treatment a phenomenological study of the experience of patients and their partners /." View thesis, 2007. http://handle.uws.edu.au:8081/1959.7/19046.

Full text
Abstract:
Thesis (M.Sc. (Hons.)) -- University of Western Sydney, 2007.
A thesis submitted towards the degree of Master of Nursing (Honours) in the University of Western Sydney, College of Health and Science, School of Nursing. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
6

Taal, Maarten Willem. "Control of Hepatitis B and C virus infection in chronic haemodialysis patients." Master's thesis, University of Cape Town, 1997. http://hdl.handle.net/11427/25675.

Full text
Abstract:
Chronic haemodialysis patients have a high prevalence of Hepatitis B and C virus infections both of which are associated with chronic liver disease and hepatocellular carcinoma Hepatitis B virus (HBV) was identified as a frequent cause of hepatitis during the early years of chronic haemodialysis therapy and strict adherence to infection control measures alone proved inadequate to control the transmission of infection between patients. A policy of regular screening of all patients and blood donations for hepatitis B surface antigen together with isolation of positive patients to separate dialysis units resulted in a significant decline in the incidence of new infections. Hepatitis B vaccination provided an important new means of protection. Despite the finding that haemodialysis patients did not respond to the vaccine as well as normal adults, randomized controlled trials showed significant protection in units with a previously high incidence of infection. Studies have identified both monocyte dysfunction and B cell inhibition by elevated levels of parathyroid hormone (PTH) as possible mechanisms for the reduced response in dialysis patients. Other factors which have been associated with this poor response include increased age, male gender, specific human leukocyte antigens, shorter time on a dialysis programme and poor nutritional status. One study has shown an increased response in patients receiving recombinant human erythropoietin and. there is in vitro evidence that nifedipine improves B cell proliferation in dialysis patients with hyperparathyroidism. Hepatitis C virus (HCV) infection in haemodialysis patients has been associated with blood transfusions in many studies. However, evidence exists that transmission between patients also occurs. There is disagreement as to what measures are necessary to prevent possible nosocomial spread. Some authors recommend isolation of HCV -infected patients to separate dialysis machines or units. There is also concern over the potential of dialyzer reuse to transmit the virus. A protocol for surveillance 0f hepatitis B and C infections was established in the dialysis unit at Groote Schuur Hospital while HCV positive patients were not isolated and reuse of dialyzers was continued for all patients. HBV -infected patients are dialyzed in a separate unit and their dialyzers are not reused. A trial of hepatitis B vaccination of all antibody negative patients was undertaken using four doses of a plasma-derived vaccine given intramuscularly at month 0,1 ,2 and 4.
APA, Harvard, Vancouver, ISO, and other styles
7

Oriolo, Giovanni. "Mood, immunity and brain connectivity in patients with chronic hepatitis C." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/668025.

Full text
Abstract:
INTRODUCTION. Sickness behavior is a highly organized adaptive strategy elicited by inflammation to support the organism’s defense against pathogens. It is characterized by changes in behavior, mood and cognition similar to those observed in patients with major depressive disorder. Despite its adaptive function, sickness behavioral changes may become prolonged and dysfunctional when the pathogen stimulus cannot be removed and may contribute to the development of depression in vulnerable patients. The study of the mechanisms linking inflammation to sickness behavior and depression would be crucial for a better understanding of the pathophysiology of depression and to develop new therapeutic approaches. HYPOTHESIS AND OBJECTIVES. Patients with a low-degree chronic inflammatory disease such as chronic hepatitis C (CHC), compared to healthy controls, would present changes in brain morphology, activity, connectivity and metabolism in areas linked to sickness behavior and depression, and that such alterations would be related to mood symptoms and inflammatory markers. The main objective of this thesis was to elucidate the clinical and neurobiological correlates of a prolonged sickness condition associated with chronic inflammation, such as CHC. STUDY 1: METHODS AND RESULTS. A systematic review with meta-analysis of neuroimaging research was conducted in CHC treatment naïve patients. A computerized literature search was performed in main databases from inception up until 1 May 2017 for peer-reviewed studies on structural or functional neuroimaging assessment of no treated patients without cirrhosis or encephalopathy, neuropsychiatric disease or substance use disorder with control group. The primary measures of interest varied according to the neuroimaging technique used and the secondary outcome were the correlation of these measures with neuropsychiatric symptoms. Meta-analysis was conducted when possible. Of 1403 records, 32 full-text articles were assessed for eligibility. The final sample was of 25 studies. The whole sample was of 509 patients of mild liver disease, and 491 healthy controls. A meta‐analysis of magnetic resonance spectroscopy studies showed increased levels of choline/creatine ratio, creatine and glutamate plus glutamine in basal ganglia and increased levels of choline/creatine ratio in centrum semiovale white matter in CHC patients. Other structural and functional brain abnormalities were also reported by individual studies as marker of neuroinflammation, oxidative stress and neuron-glia or axon-myelin integrity disruption. Central nervous system metabolic changes were mainly correlated with neurocognitive impairment and fatigue symptoms, thought controversial results were observed. STUDY 2: METHODS AND RESULTS. A cross-sectional, case-control study of 35 CHC no treated patients, and 30 healthy controls, age and sex matched. Exclusion criteria were decompensated cirrhosis or hepatocarcinoma, any chronic disease or inflammatory condition, any neuropsychiatric and substance use disorder. All patients were evaluated for perceived stress (PSS), depression (PHQ-9), fatigue and irritability through a visual analog scale (VAS), as well as serum levels of interleukin-6 (IL-6), prostaglandin E2 (PGE2) and oxidative stress markers. Functional magnetic resonance imaging was performed, measuring resting-state functional connectivity using a region-of-interest (seed)-based approach focusing on the bilateral insula, subgenual anterior cingulate cortex (sgACC) and bilateral putamen. Between-group differences in functional connectivity patterns were assessed with two-sample t-tests, while the associations between symptoms, inflammatory markers and connectivity patterns were analyzed with multiple regression analyses. We observed that CHC patients had higher PSS, PHQ-9 and VAS scores for fatigue and irritability, as well as increased IL-6 levels, PGE2 concentrations and antioxidant system activation compared to controls. Increased perceived stress and depressive symptoms were associated with changes in inflammatory marker levels and in functional connectivity between the insula and putamen, areas involved in interoceptive integration, emotional awareness, and orientation of motivational state. Of note, PGE2 and PSS scores accounted for 46% of the variance in functional connectivity between the anterior insula and putamen. CONCLUSIONS. The results supported the hypothesis of a direct or indirect involvement of hepatitis C virus in central nervous system disturbances and provide valuable information on the brain areas involved in perceived stress, fatigue and subclinical depressive symptoms during chronic inflammation, highlighting the crucial role of interoception in coordinating prolonged sickness behavior. Using the CHC disease as a model of low-grade inflammation, new neurobiological and neuroanatomical links between sickness behavior and chronic inflammatory conditions have been elucidated. These findings may be crucial in understanding pathophysiological mechanisms related with psychiatric diseases such as depression and open new research perspectives centered on the development of new therapeutic targets.
INTRODUCCIÓN. La conducta de enfermedad es una estrategia adaptativa y coordinada que tiene la finalidad de defender el organismo en contra de agente patógenos. Los cambios conductuales pueden persistir de forma prolongada y volverse disfuncionales. El estudio de los mecanismos subyacentes que relacionan la inflamación, conducta de enfermedad y depresión mejoraría el conocimiento de la fisiopatología de la depresión. HIPÓTESIS Y OBJETIVOS. Los pacientes con hepatitis C crónica (HCC) podrían presentar cambios cerebrales a nivel estructural, funcional, conectividad y metabolismo en áreas asociadas con la conducta de enfermedad y la depresión, y dichas alteraciones podrían estar relacionadas con síntomas anímicos y marcadores inflamatorios. El objetivo de esta tesis es elucidar los correlatos clínicos y neurobiológicos de la conducta de enfermedad prolongada asociada a HCC. ESTUDIO 1: MÉTODOS Y RESULTADOS. Realizamos revisión sistemática con meta-análisis de estudios sobre neuroimagen en pacientes con HCC no tratados. Se llevó a cabo una búsqueda computerizada de los estudios de neuroimagen publicados en las principales bases de datos. La variable primaria dependió de la técnica de neuroimagen utilizada. De 1403 estudios encontrados, 25 fueron seleccionados. La muestra final comprendió 509 pacientes con HCC y 491 controles sanos. En los meta-análisis de los estudios de espectroscopia se observaron niveles incrementados de la ratio entre colina y creatina, de la creatina y de glutamato plus glutamina en los ganglios basales de pacientes. Las alteraciones metabólicas en el sistema nervioso central estaban relacionadas a alteraciones neurocognitivas de forma controvertida. ESTUDIO 2: MÉTODOS Y RESULTADOS. Estudio transversal, caso-control, que compara 35 pacientes de ambos sexos, entre 18 y 55 años, con HCC sin tratar y 30 controles sanos. Se evaluaron el estrés percibido (PSS), depresión (PHQ-9), fatiga e irritabilidad mediante escala visual analógica (VAS), así como las concentraciones séricas de interleuquina-6 (IL-6), prostaglandina E2 (PGE2) y marcadores de estrés oxidativo. Se realizó una resonancia magnética cerebral funcional estudiando la conectividad cerebral en estado de reposo, mediante la selección a priori de regiones de interés: ínsula bilateral, cortex cingulado anterior subgenual (sgACC), y el putamen bilateral. Las asociaciones entre síntomas clínicos, marcadores inflamatorios y patrones de conectividad funcional fueron analizadas mediante regresión múltiple. Los pacientes con HCC presentaban puntuaciones mayores en las escalas de PSS, PHQ-9, VAS-F y VAS-I, un incremento de las concentraciones séricas de IL-6 y PGE2 y una mayor activación del sistema anti-oxidativo comparado con los controles sanos. El incremento del estrés percibido y los síntomas depresivos estaban asociados a alteraciones de los marcadores inflamatorios y de la conectividad entre ínsula y putamen. Los niveles de PGE2 y los valores de PSS eran responsables del 46% de la variación de la conectividad funcional entre ínsula anterior y putamen. CONCLUSIONES. Los resultados observados proporcionan información importante sobre las áreas cerebrales involucradas en el estrés percibido y los síntomas depresivos subclínicos durante un estado de inflamación crónica. Se han podido ilustrar nuevos enlaces neurobiológicos y neuroanatómicos entre la conducta de enfermedad e la inflamación crónica que podrían ayudar en la comprensión de mecanismos fisiopatológicos relacionados con la depresión, y abrir nuevas perspectivas de investigación centradas en el desarrollo de nuevas dianas terapéuticas.
APA, Harvard, Vancouver, ISO, and other styles
8

Okwor, Chisom Ifeoma Adaeze. "Understanding Immune Suppression in Patients with Chronic Hepatitis C Virus Infections." Thesis, Université d'Ottawa / University of Ottawa, 2021. http://hdl.handle.net/10393/41856.

Full text
Abstract:
Hepatitis C Virus (HCV) is a small RNA virus that progresses to chronicity in 50-80% of infected individuals. Direct-acting antivirals (DAAs) are revolutionary treatments for HCV with 90-98% cure rates. However, over time, chronic HCV infections can result in advanced liver disease, including cirrhosis. Patients with advanced fibrosis experience a poor response to vaccination, recurrent infections and increased risk for hepatocellular carcinoma (HCC). These outcomes are, in part, a consequence of immune dysfunction. Increased inhibitory receptor and Galectin-9 (GAL-9) expression is a possible mechanism promoting lymphocyte dysfunction. In this study, blood samples were collected from chronic HCV patients with different degrees of liver fibrosis. I conducted a 13-parameter flow stain on the peripheral blood mononuclear cells (PBMC) of these patients. Next, I measured the expression of inhibitory receptors (PD-1, CTLA-4, LAG-3, TIGIT and TIM-3) and GAL-9 on bulk T cell and NK cells of 15 chronic HCV patients with no to moderate fibrosis (F0-F2) and 15 with advanced fibrosis (F3-F4). To analyze receptor co-expression, I employed t-distributed stochastic neighbor embedding (t-SNE) analysis to dimensionally reduce the multi-parametric data. Notably, I found that F3-F4 patients had higher frequencies of >3 inhibitory receptor co-expression on NK cells. Moreover, t-SNE analysis of bulk T cells revealed that F3-F4 patients manifest a higher frequency of cells in the clusters with CD25+TIGITmed-hi CD4+ T cells and PD-1medLAG-3med-hiGAL-9med-hi CD4+ T cells. t-SNE analysis of NK cells also showed that F3-F4 patients manifest a higher frequency of cells in the cluster with CD25+TIGITmed-hiTIM-3med-hi CD56Dim NK cells and CCR7+ PD-1medLAG-3med-hiGAL-9med-hi CD56Dim NK cells. Lastly, the frequency of cells in these clusters was found to positively correlate with patient’s extent of liver damage. In conclusion, I identified phenotypes of immune dysregulation that could explain the increased susceptibility to infection and HCC in chronic HCV patients with advanced fibrosis. These phenotypes could identify targets for combinatorial checkpoint blockade therapy to potentially improve immune function in these patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Lindahl, Karin. "Ribavirin - dose and concentration in treatment of chronic hepatitis C infected patients /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-348-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hayashi, Hisao, Toshikuni Takikawa, Noriko Arai, and Motoyoshi Yano. "The Advantage of Gastrectomized Patients in Management of their Chronic Hepatitis C." 名古屋大学医学部, 1997. http://hdl.handle.net/2237/6187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hepatitis C – Patients"

1

Napolitano, Ralph. Hepatitis C survival secrets: With critical insights your doctor won't share. Pine Bush, NY: HTX, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Smith, Suzy. Hepatitis C through a patient's eyes: Hope for healing. Livermore, CA: WingSpan Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Scheu, Gerhard. Deliktische Produktverantwortung für Hepatitis C-Infektionen hämophiler Patienten. Baden-Baden: Nomos, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

New South Wales. Anti-Discrimination Board. C change: Report of the enquiry into hepatitis C related discrimination. [Sydney]: The Board, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pozitivno. Sofii︠a︡: Bŭlgarski pisatel, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mullah, Nadiah Mohammad Ali. A study of the incidence of viral hepatitis B and C in patients undergoing haemodialysis in Jeddah. Salford: University of Salford, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mohamed Hatem Fathi El-Saied Wali. Natural history, factors affecting severity and progression rate of hepatitis c virus (HCV) infection in liver transplanted and non-transplanted patients. Birmingham: University of Birmingham, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Parker, James N., and Philip M. Parker. The 2002 official patient's sourcebook on hepatitis C. Edited by Icon Group International Inc and NetLibrary Inc. San Diego, Calif: Icon Health Publications, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Office, General Accounting. VA health care: Further efforts needed to improve hepatitis C testing for at-risk veterans : report to the Chairman, Subcommittee on National Security, Emerging Threats, and International Relations, Committee on Government Reform, House of Representatives. Washington, D.C: United States General Accounting Office, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Office, General Accounting. VA health care: Improvements needed in hepatitus C disease management practices : report to the Chairman, Subcommittee on National Security, Veterans Affairs, and International Relations, Committee on Government Reform, House of Representatives. Washington, D.C: United States General Accounting Office, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Hepatitis C – Patients"

1

Asselah, T., and Dominique Salmon-Ceron. "Pretherapeutic Evaluation of the Patients with HCV Infection." In Viral Hepatitis: Chronic Hepatitis C, 59–64. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mete, Bilgul, and Fehmi Tabak. "Treatment of Hepatitis C Virus-Infected Patients with Renal Failure." In Viral Hepatitis: Chronic Hepatitis C, 97–107. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

AlJuboori, Alhareth, Satinder Kaur, and Veysel Tahan. "Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients." In Viral Hepatitis: Chronic Hepatitis C, 65–95. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Martin, Paul, and Fabrizio Fabrizi. "Chronic HCV in Patients with Renal Disease." In Chronic Hepatitis C Virus, 93–102. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1192-5_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Roche, Bruno, Audrey Coilly, and Didier Samuel. "Management of Transplant Patients Infected with HCV." In Hepatitis C: Care and Treatment, 153–73. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67762-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cornberg, Markus. "Management of Patients with Acute Hepatitis C." In Hepatitis C: Care and Treatment, 141–52. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67762-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Verna, Elizabeth C., and Robert S. Brown. "Use of HCV-Positive Organs in Patients With and Without Chronic HCV." In Chronic Hepatitis C Virus, 291–300. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1192-5_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Asselah, Tarik. "Current Management of Patients with HCV Genotype 4." In Hepatitis C: Care and Treatment, 119–27. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67762-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Asselah, Tarik, and Patrick Marcellin. "Current Management of Patients with HCV Genotype 1." In Hepatitis C: Care and Treatment, 75–82. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67762-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mangia, Alessandra, and Valeria Piazzolla. "Current Management of Patients with HCV Genotype 2." In Hepatitis C: Care and Treatment, 83–95. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67762-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hepatitis C – Patients"

1

Nevkhoroshev, Yevhen, and Deonis Tkemaladze. "AUTOIMMUNE THYROIDITIS IN PATIENTS WITH CHRONIC HEPATITIS C." In TENDANCES SCIENTIFIQUES DE LA RECHERCHE FONDAMENTALE ET APPLIQUÉE, Chair Lilia Bobro. European Scientific Platform, 2020. http://dx.doi.org/10.36074/30.10.2020.v2.07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cabo, Domingos Jose Vaz Do, Silvia Helena Grosso Esher, Maria Filomena Xavier Mendes, Romeu Carillo Jr, and Maria Solange Gosik. "Developing Homeopathic Treatment Guidelines for Patients with Hepatitis C." In HRI London 2019—Cutting Edge Research in Homeopathy: Presentation Abstracts. The Faculty of Homeopathy, 2020. http://dx.doi.org/10.1055/s-0040-1702136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gil-Sierra, MD, F. Tellez-Perez, E. Rios-Sanchez, MDP Briceño-Casado, S. Fenix-Caballero, C. Martinez-Diaz, EJ Alegre-Del Rey, et al. "4CPS-085 Stewardships of hepatitis c virus patients in prisons." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.234.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dalkilic, E., M. Gullulu, G. Karadogan, M. Yavuz, K. Dilek, A. Ersoy, and M. Yurtkuran. "FRI0152 Criyoglobulinemia in hepatitis c infective hemodialysis and renal transplantation patients." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"3.0T 1H MRS in Assessing the Steatosis in Chronic Hepatitis C Patients." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.64.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Al-antari, Mugahed A., Mohammed A. Almasani, Hani M. Bu-Omer, and Khaled K. Wahba. "A system dynamics based model for hepatic fibrosis in hepatitis C patients." In 2016 33rd National Radio Science Conference (NRSC). IEEE, 2016. http://dx.doi.org/10.1109/nrsc.2016.7450871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Holstein, Katharina, Leonora Witt, Tim Rolvien, Michael Amling, Florian Barvencik, Anna Matysiak, and Florian Langer. "Impact of Hepatitis C Infection on Bone Microstructure of Patients with Hemophilia." In Hamburger Hämophilie Symposion Hamburg, Germany. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1721588.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hogg, Sarah, Shion Gosrani, Rachael Forbes, Kate Hallsworth, Matthew D. Campbell, and Stuart McPherson. "P193 Patients with hepatitis C are at high risk of cardiovascular events." In Abstracts of the BSG Campus, 21–29 January 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2020-bsgcampus.268.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mckee, Geoff, Nuria Chapinal, Zahid Butt, Carmine Rossi, Stanley Wong, Mark Gilbert, Jason Wong, et al. "P388 Evolution of hepatitis C care cascades among HIV and hepatitis B co-infected patients in british columbia, canada." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Huang, Jian, Kathleen O'Sullivan, Elizabeth Kenny-Walsh, Orla Crosbie, John Levis, and Liam J. Fanning. "Nonlinear Mixed Effects Modelling Viral Load in Untreated Patients with Chronic Hepatitis C." In 2008 2nd International Conference on Bioinformatics and Biomedical Engineering. IEEE, 2008. http://dx.doi.org/10.1109/icbbe.2008.625.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hepatitis C – Patients"

1

Holtzmuller, Kent. Utilization of Telemedicine for Evaluation and Treatment of Hepatitis C Patients in Military Health Clinics. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada396498.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Holtzmuller, Kent. Utilization of Telemedicine for Evaluation and Treatment of Hepatitis C Patients in Military Health Clinics. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada392494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Terzieva, Kalina, Metody Kunchev, Hristina Hitkova, Tzetza Doichinova, Tanya Petkova, Krasimira Mekoushinov, and Dimitar Shalamanov. Molecular-genetic Indicators as Part of an Epidemiologic Study on Patients with Virus Hepatitis C. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, April 2021. http://dx.doi.org/10.7546/crabs.2021.04.15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Evon, Donna, Jipcy Amador, Paul Stewart, Bryce Reeve, Carol Golin, Anna Lok, Richard Sterling, et al. Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study. Patient-Centered Outcomes Research Institute® (PCORI), July 2020. http://dx.doi.org/10.25302/06.2020.cer.140820660.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xu, Yan, Yuyang Zhao, Yong Wang, Changyu Zhou, Xingang Wang, Yongqiang Dong, and Shaoyou Qin. Concurrent hepatic steatosis increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B or C virus infection: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hepatitis C – Patients' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography